Pharmaceuticals and the stock market may seem like two completely different worlds to beginner investors, but Eli Lilly and Company proves otherwise.
Its stock has delivered exceptional growth in recent years. The company generates tens of billions of dollars in revenue, and its market capitalization has surpassed $1 trillion.
But after such a strong rally, an important question arises: how to buy Eli Lilly stock? Is it still worth adding to your portfolio at current prices? What is the difference between buying shares outright and trading CFDs? And when does Eli Lilly pay dividends?
This article covers everything from the company’s history to a step-by-step guide to investing in Eli Lilly and trading its stock.
The article covers the following subjects:
Major Takeaways
-
Eli Lilly was founded in the United States in 1876 and operates in the pharmaceutical industry. It is considered a blue-chip company and has paid dividends consistently for more than a century.
-
LLY’s market capitalization exceeds $1 trillion.
-
Its shares trade in the four-digit range, making LLY one of the highest-priced stocks on the market.
-
The company’s flagship products include Mounjaro for diabetes treatment and Zepbound for weight management.
-
LLY shares are listed on the New York Stock Exchange (NYSE). Eli Lilly CFDs can be traded through a LiteFinance brokerage account. LiteFinance clients can buy fractional shares starting from $10 and trade CFDs with leverage.
-
The stock’s dividend yield is modest at less than 1%. However, the company has increased its dividend for many years and pays dividends quarterly.
-
Eli Lilly’s P/E ratio is above 40x. This relatively high valuation reflects expectations of double-digit revenue and earnings growth.
-
Analysts remain bullish on LLY stock and continue to rate it a Buy.
What Is Eli Lilly and Company (LLY)?
Eli Lilly and Company is one of the world’s oldest pharmaceutical giants. Founded in 1876 by Colonel Eli Lilly, a Civil War veteran dissatisfied with the quality of medicines available at the time, the company has grown into a global healthcare leader. Nearly 150 years later, its name is associated with medicines that improve and save millions of lives while generating billions of dollars in revenue.
Headquartered in Indianapolis, Indiana, Eli Lilly sells its products in more than 120 countries and employs approximately 50,000 people worldwide.
The company focuses on several therapeutic areas, including cardiometabolic health (diabetes and obesity), oncology, immunology, and neuroscience. Its biggest success, however, comes from GLP-1 therapies based on tirzepatide—synthetic analogs of naturally occurring hormones.
Mounjaro (tirzepatide) is approved for the treatment of diabetes, while Zepbound contains the same active ingredient but is approved for chronic weight management. Both drugs have demonstrated remarkable efficacy, with patients losing up to 20% of their body weight —results previously achievable only through surgery.
Eli Lilly’s main competitor is the Danish pharmaceutical company Novo Nordisk, whose flagship products include Ozempic and Wegovy. The race for leadership in the weight-loss drug market has become one of the most competitive segments of the global pharmaceutical industry. Analysts estimate that this market could reach $100 billion by 2030.
Beyond its GLP-1 portfolio, Eli Lilly also offers treatments for plaque psoriasis (Taltz), migraine (Emgality), Alzheimer’s disease (Kisunla), and several types of cancer. This diversified portfolio helps reduce business risk, as the company’s performance does not depend on a single product.
Kisunla deserves special attention. Approved by the U.S. Food and Drug Administration (FDA) for the treatment of early-stage Alzheimer’s disease, the drug could open another multibillion-dollar growth opportunity for Eli Lilly if sales continue to expand.
Eli Lilly Stock Trading Technical Information
Eli Lilly shares are listed on the New York Stock Exchange (NYSE) under the ticker LLY. The stock is included in the S&P 500 and Dow Jones Industrial Average indices.
Its current share price exceeds $1,000, placing it in the four-digit range. This makes it one of the highest-priced stocks on the market. For retail investors, buying a whole share may represent a significant investment. One possible solution is to buy fractional shares. Eli Lilly CFDs can also be traded on LiteFinance platforms, with positions starting at $10.
The stock’s 52-week range is between $624 and $1,238. Its beta coefficient is 0.52, indicating that the stock is roughly half as volatile as the overall market. The defensive nature of LLY shares appeals to conservative investors, as Eli Lilly stock has generally outperformed the broader market, even during market sell-offs.
Eli Lilly’s P/E ratio exceeds 40x. This is a high valuation that reflects expectations of earnings growth in the coming years. By comparison, the average P/E ratio for the pharmaceutical sector is around 20x. This suggests that investors are willing to pay a premium for Eli Lilly’s leadership in the GLP-1 segment. However, if growth expectations are not met, investors may end up buying the stock at an inflated price.
|
Parameter |
Value |
|
Ticker |
LLY |
|
Exchange |
NYSE |
|
Sector |
Healthcare / Pharmaceuticals |
|
Founded |
1876 |
|
Employees |
~50,000 |
|
P/E (trailing) |
~43 |
|
P/E (forward) |
~27 |
|
Beta |
~0.5 |
|
Dividend Yield |
~0.6% |
|
Revenue (FY 2025) |
$72.3 billion (+55.5%) |
|
Net Income (FY 2025) |
$25.3 billion |
|
Key Products |
Mounjaro, Zepbound, Taltz, Emgality |
|
Key Competitor |
Novo Nordisk (Ozempic, Wegovy) |
Main Shareholders of Eli Lilly
Eli Lilly’s largest shareholders are institutional investors. The three biggest are Vanguard Group, BlackRock, and State Street —a classic lineup for a U.S. blue-chip company. Together, they own a significant share of the company’s outstanding stock.
Large stakes are also held by mutual funds, pension funds, and insurance companies. Retail investors make up a smaller portion of the shareholder base, although their share is growing thanks to the availability of fractional shares.
Insider ownership is relatively low. The company’s management owns only a small fraction of its outstanding shares. This is standard practice for mature public companies with market capitalizations exceeding $1 trillion.
For individual investors, this means investing in a company managed by experienced professionals and overseen by the world’s largest institutional shareholders. Transparency and stability are hallmarks of LLY.
Why Invest in Eli Lilly Stock?
Why do investors around the world choose Eli Lilly stock? Here are four compelling reasons:
-
Strong revenue and earnings growth. Mounjaro and Zepbound are reshaping the weight-loss drug market. Obesity is a global challenge, and demand for effective treatments is expected to continue growing. Alongside Novo Nordisk, Eli Lilly is at the center of this trend.
-
Diversified product portfolio. Beyond its GLP-1 therapies, the company offers dozens of medicines for oncology, immunology, and neurology. Even if competition in the weight-loss segment intensifies, Eli Lilly’s broad business helps support its revenue.
-
Dividends. The company has consistently increased its dividend for many years. Although the dividend yield is modest, the reliability and growth of its payouts make the stock attractive for long-term investors.
-
Share repurchases. Eli Lilly actively reduces its number of outstanding shares. Fewer shares increase earnings per share for the remaining shareholders, providing steady long-term support for the stock price.
Is Eli Lilly stock a good buy right now? Analysts see upside potential from current price levels and maintain a Buy rating. Price targets vary widely, ranging from conservative to optimistic estimates. The investment decision, however, is ultimately yours. Add the potential of Kisunla, the company’s Alzheimer’s treatment, and the outlook becomes even more compelling. The market for dementia treatments is estimated to be worth tens of billions of dollars.
Where and How to Buy Eli Lilly Stock
How can individual investors buy Eli Lilly stock? Here is a step-by-step guide:
-
Open a brokerage account. Register with LiteFinance or another licensed broker that provides direct access to NYSE market quotes. You will need to provide your email address, phone number, proof of identity, and, in some cases, proof of address. The account opening process takes only a few minutes. Once registered, you will have access to your personal profile, where you can view your trading history, orders, reports, and statistics in one place.
-
Fund your account. The minimum deposit is $50. LiteFinance accepts bank cards, bank transfers, and electronic wallets. Funds are credited instantly with no commission, and your balance will appear immediately in your personal profile.
-
Find the Eli Lilly ticker. Enter LLY in the LiteFinance platform search bar. The platform will display the current price, daily, weekly, monthly, and yearly charts, as well as the order book.
-
Choose how to invest. You can buy Eli Lilly shares directly through your broker using either a market or a limit order. Alternatively, you can trade Eli Lilly CFDs, allowing you to invest in fractional shares starting from $10.
Another option is to invest through ETFs that hold Eli Lilly stock. Exchange-traded funds such as the iShares U.S. Pharmaceuticals ETF (IHE) and the Health Care Select Sector SPDR Fund (XLV) allocate a significant portion of their portfolios to LLY. This approach provides diversification, giving you exposure to dozens of pharmaceutical companies through a single investment. LLY can serve as the core of a portfolio, but it should not be the only holding.
How to Trade Eli Lilly (LLY) Stock CFDs
In addition to buying shares directly, LLY stock is available through CFDs (Contracts for Difference). CFDs allow traders to use leverage, meaning only a fraction of the stock’s value—typically 5–20%—is required to open a position. Both potential profits and losses increase proportionally.
Advantages of Eli Lilly CFDs:
-
Access to a high-priced stock with a small amount of capital.
-
The ability to open short positions and profit from falling prices.
-
Instant execution without waiting for T+2 settlement.
-
No need to open a separate NYSE brokerage account.
-
Trading is available 24/5 through the LiteFinance platform.
Disadvantages of CFDs:
-
Overnight swap charges.
-
Leverage increases both profits and losses.
-
You do not become a shareholder and are not entitled to dividends.
-
Successful CFD trading requires experience and disciplined risk management.
Want to try it without risk? Open a demo account—your personal profile can be created without registration. Virtual funds allow you to test leveraged CFD trading in a risk-free environment. It’s the best way to find out which investment instrument suits you best.
Eli Lilly Dividends & What to Know Before Buying
Dividends are an important part of the Eli Lilly investment story. The company has paid dividends continuously for more than a century. Few stocks on the market can match that level of consistency. Alongside companies such as Coca-Cola, Procter & Gamble, and Johnson & Johnson, Eli Lilly is considered one of the world’s most reliable dividend payers.
When Does Eli Lilly Pay Dividends? Dividends are paid four times a year. The payment cycle follows the standard sequence: dividend declaration date → ex-dividend date → payment date. Eli Lilly’s dividend yield is modest—less than 1% per year. It is not a stock for investors seeking dividends as their primary source of income.
Investors buy LLY for capital appreciation, while dividends are a bonus rather than the main objective. However, the pace of dividend growth is impressive. The company has increased its dividend at double-digit rates for several consecutive years. If this trend continues, investors’ dividend returns on their original investment will increase over time.
One tax consideration: non-U.S. investors are subject to dividend withholding tax. Check the current terms and conditions in your broker’s client area.
Conclusion
Buying Eli Lilly stock today means investing in a company with nearly 150 years of history, a trillion-dollar market capitalization, and a unique portfolio of medicines. Mounjaro, Zepbound, and other products provide a strong foundation for long-term growth.
However, there are risks. A high P/E ratio, competition from Novo Nordisk, and regulatory challenges are among the key ones. At the same time, revenue and earnings continue to grow at double-digit rates, while the company has paid dividends without interruption for decades. This is why analysts recommend buying the stock.
Eli Lilly is not a speculative investment. It is a stock for a long-term portfolio. At the same time, CFDs offer opportunities for short-term trading. Buying shares directly is a long-term investment, while pharmaceutical ETFs provide diversification. The choice of instrument depends on your investment goals.
Open a LiteFinance demo account today—your personal profile is activated instantly without registration. Find the LLY ticker in the trading platform, explore the chart, and take your first step. Stocks like these do not often attract the attention of retail investors.
Price chart of LLY in real time mode
The content of this article reflects the author’s opinion and does not necessarily reflect the official position of LiteFinance broker. The material published on this page is provided for informational purposes only and should not be considered as the provision of investment advice for the purposes of Directive 2014/65/EU.
According to copyright law, this article is considered intellectual property, which includes a prohibition on copying and distributing it without consent.
